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P2Y12 expression and function in
alternatively activated human microglia
ABSTRACT
Objective: To investigate and measure the functional significance of altered P2Y12 expression in
the context of human microglia activation.
Methods: We performed in vitro and in situ experiments to measure how P2Y12 expression can
influence disease-relevant functional properties of classically activated (M1) and alternatively
activated (M2) human microglia in the inflamed brain.
Results:We demonstrated that compared to resting and classically activated (M1) human microg-
lia, P2Y12 expression is increased under alternatively activated (M2) conditions. In response to
ADP, the endogenous ligand of P2Y12, M2 microglia have increased ligand-mediated calcium
responses, which are blocked by selective P2Y12 antagonism. P2Y12 antagonism was also
shown to decrease migratory and inflammatory responses in human microglia upon exposure to
nucleotides that are released during CNS injury; no effects were observed in human monocytes
or macrophages. In situ experiments confirm that P2Y12 is selectively expressed on human
microglia and elevated under neuropathologic conditions that promote Th2 responses, such as
parasitic CNS infection.
Conclusion: These findings provide insight into the roles of M2 microglia in the context of neuro-
inflammation and suggest a mechanism to selectively target a functionally unique population of
myeloid cells in the CNS. Neurol Neuroimmunol Neuroinflamm 2015;2:e80; doi: 10.1212/
NXI.0000000000000080
GLOSSARY
BSA 5 bovine serum albumin; [Ca21]I 5 intracellular calcium; CSF 5 colony-stimulating factor; FBS 5 fetal bovine serum;
IFN 5 interferon; IL 5 interleukin; LPS 5 lipopolysaccharide; MDM 5 monocyte-derived macrophage; mRNA 5 messenger
RNA; MS 5 multiple sclerosis; TNF 5 tumor necrosis factor.
In vitro studies have previously demonstrated several phenotypic and functional differences
between human monocyte-derived macrophages (MDMs) and microglia in the context of cell
migration, phagocytosis, and immunoregulatory and effector functions.1–6 The distinct proper-
ties of myeloid cell subtypes suggest that they may differentially contribute to mechanisms
related to both CNS injury and repair. While several technologies enable us to distinguish
between different myeloid cell subpopulations in mice7–9 and have contributed to our under-
standing of myeloid cell origin and function, they have yet to provide direct translation and
relevance in humans.
P2Y12 has been identified as a receptor that robustly distinguishes microglia from other mye-
loid lineage cells.10 The P2Y12 receptor is an ADP-responsive G protein–coupled receptor
expressed on the surface of platelets and is the pharmacologic target of several antithrombotic
agents.11 In the CNS, P2Y12 expression is limited to the ramified processes of microglia, which
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likely facilitates the detection of nucleotides
upon injury.12 It is interesting that loss of
P2Y12 expression in microglia results in
decreased process extension and migration fol-
lowing focal injury.12,13 In humans, the role of
P2Y12 expression in microglia is unknown.
Herein, we investigated the significance of
P2Y12 expression in the context of human
brain injury and repair. Our results confirm
that P2Y12 is a unique marker of human
microglia, increases following interleukin
(IL)-4 and IL-13 activation, and mediates cell
migration and inflammatory responses. Iden-
tifying P2Y12 as a molecule associated with
the M2 tissue regenerative phenotype14–16
may help to discover novel therapeutic targets
and mechanisms that promote CNS repair.
METHODS Standard protocol approvals, registrations,
and patient consents. All institutional ethics approval was ob-
tained according to Canadian Institutes of Health Research
guidelines.
Human fetal and adult microglia isolation, culture, and
polarization. Human fetal brain tissue was obtained from the Fetal
Tissue Repository (Albert Einstein College ofMedicine, Bronx, NY).
Human adult microglia were isolated from healthy brain tissue of pa-
tients undergoing brain surgery for intractable epilepsy. Human fetal
and adult microglia were cultured in 5% DMEM and 5%
MEM, respectively, with 5% fetal bovine serum (FBS), penicillin/
streptomycin, and glutamine. Cell polarization was performed over
48 hours, according to previously published methods.1,17 Briefly,
microglia were polarized to the M1 phenotype using granulocyte
macrophage colony-stimulating factor (GM-CSF) (5 ng/mL),
interferon (IFN)-g (20 ng/mL), and lipopolysaccharide (LPS)
(serotype 0127:B8, 100 ng/mL). M2 cells were polarized using
macrophage colony-stimulating factor (M-CSF) (25 ng/mL), IL-4
(20 ng/mL), and IL-13 (20 ng/mL).
Human MDM culture and polarization. Human peripheral
blood mononuclear cells were isolated by Ficoll separation from
the blood of healthy volunteers. CD141 cells were positively
selected using immunomagnetic bead selection (Miltenyi Biotec,
Auburn, CA). Macrophage differentiation was performed over 5
days by culturing monocytes (5 3 105 cells/mL) in RPMI
supplemented with 10% FBS, M-CSF (25 ng/mL), penicillin/
streptomycin, and glutamine. MDMs were polarized using the
protocol described above.
Immunocytochemistry/immunohistochemistry. Immuno-
cytochemistry was performed using a rabbit polyclonal anti-
P2Y12 antibody10 (generated by Dr. H. Weiner, Harvard
University, Cambridge, MA), a monoclonal anti-CD68
antibody (Dako, Burlington, Ontario, Canada; 1:100), and
appropriate secondary antibodies. For human brain sections,
slides were deparaffinized and antigen retrieval was performed
using a 0.01 M sodium citrate buffer solution (pH 6.0) for
15 minutes in the microwave on high setting.
RNA isolation and reverse transcription quantitative real-
time PCR. Total RNA was isolated using standard Trizol
protocols and DNase-treated (Qiagen, Germantown, MD).
TaqMan quantitative real-time PCR was used to measure
messenger RNA (mRNA) expression levels for all mRNAs.
Relative gene expression data were calculated according to the
DDCt method.18
Flow cytometry. Human microglia were collected by gently
scraping and blocked in FACS buffer supplemented with 10%
normal human serum and normal mouse IgG (3 mg/mL). Cells
were then incubated at 4°C for 30 minutes with either a control
isotype antibody directly conjugated with Alexa647 (BD Bio-
sciences, Mississauga, Ontario, Canada) or a polyclonal rabbit
anti-P2Y12 antibody (1:100) followed by an anti-IgG1-
Alexa647 (1:100). After washing, cells were fixed in 1%
formaldehyde and flow cytometry was performed using a
FACSCalibur (BD Biosciences).
Ratiometric measurement of intracellular calcium.
Microglia were loaded with fura-2 AM (5 mM, Molecular
Probes, Life Technologies, Grand Island, NY) in Ringer
solution containing NaCl (130 mM), KCl (5 mM), CaCl2
(2 mM), MgCl2 (1 mM), HEPES (10 mM), glucose (8 mM)
(pH 7.4), and 1% bovine serum albumin (BSA) for 30 minutes
at 37°C. Prior to imaging, microglia were washed and incubated
for an additional 30 minutes. Fluorescence was measured at 510
nm and recorded with a high-resolution camera (CoolSNAP
HQ2, Roper Scientific/Photometrics, Tucson, AZ). Pairs of 340
nm and 380 nm images were acquired and calculated using
Metafluor 7.0 software (Molecular Devices, Sunnyvale, CA).
The 340/380 nm emission ratios were proportional to
intracellular calcium levels.
Cell migration assays. Migration assays were performed using
Boyden-type 96-well plates according to manufacturer’s
instructions (Neuro Probe, Gaithersburg, MD). Cells were
suspended in media containing 0.5% BSA for 1 hour and
pretreated with PSB0739 (10 mM) or vehicle (DMSO). ATP
or ADP (1–300 mg/mL) was added to induce chemotaxis.
Polycarbonate filters (10 mm [microglia] or 5 mm [monocytes]
pore size) were placed in contact with media and cells were added
(106 cells/mL) atop the filter. Following incubation (4 hours at
37°C), the filter surface was washed, fixed with 2% PFA, and
stained using a 0.04% crystal violet.
Migration studies were also performed using microfluidic
chambers with 10-mm diameter channels (1 mm in length)
(ANANDA, McGill University, Montreal, Quebec, Canada).
Microglia were pretreated with either PSB0739 (10 mM; R&D
Systems, Minneapolis, MN) or vehicle for 1 hour and then plated
(106 cells/mL) in the upper chamber. Media alone or media
containing ADP (300 mM) was added to the lower chamber as
a chemotactic agent. Following 3 days and supplementing ADP
each day, cells were fixed, washed, and stained with DAPI and a
FITC-conjugated CD68 antibody (1:40, BD Biosciences).
Images were visualized using fluorescence microscopy (Leica,
Wetzlar, Germany) and OpenLab software (PerkinElmer,
Waltham, MA). The distance within the migration chamber for
each nucleated cell was measured.
ELISAs. Human tumor necrosis factor (TNF) and IL-6 ELISAs
were performed according to the manufacturer’s instructions (BD
Biosciences). LPS activation (100 ng/mL) was used in all
experiments as a positive control. All results are presented as
percent of maximal response relative to ADP treatment (200 mM).
Statistics. All statistical analyses were performed using Prism 5.0
(GraphPad Software, La Jolla, CA). Data are presented as mean
6 SEM. A one-way analysis of variance with Tukey post hoc
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tests or unpaired Student t test was used to determine differences
between the experimental conditions; p , 0.05 was considered
statistically significant.
RESULTS P2Y12 expression is significantly elevated in
human microglia compared to MDMs. Compared to
MDMs, P2Y12 expression was highly elevated in
both fetal and adult microglia. Delta cycle threshold
values were significantly lower in both human fetal
and adult microglia compared with MDMs, indica-
tive of greater expression (figure 1A). To confirm
protein expression, co-immunocytochemistry was
performed using anti-CD68 and anti-P2Y12
antibodies. Human microglia positively stained for
P2Y12, while no staining was observed for MDMs
(figure 1B). As a positive control, rat microglia
positively stained for P2Y12, as previously
described10 (figure e-1A at Neurology.org/nn).
Alternatively polarized “M2” human microglia
significantly upregulate P2Y12 expression. To determine
whether activation of human microglia influenced
Figure 1 P2Y12 expression is significantly elevated in human microglia compared to monocyte-derived
macrophages
(A) Using TaqMan quantitative real-time PCR, P2Y12 expression was measured in RNA isolated from resting human mon-
ocyte-derived macrophages and microglia (both fetal and adult). Compared to monocyte-derived macrophages, delta cycle
threshold (CT) values were much lower in both human fetal and adult microglia populations, which is indicative of higher
P2Y12 expression. Error bars represent mean 6 SEM; n 5 4 samples/condition; ****p , 0.0001. (B) Using immunocyto-
chemistry, resting CD681 human microglia expressed P2Y12; no immunoreactivity was observed in resting macrophages.
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expression of P2Y12, cells were polarized to either
M1 (classical activation) or M2 (alternative activa-
tion). Compared to unpolarized microglia, P2Y12
mRNA expression was significantly increased in
M2-polarized cells (10-fold change in adult
microglia [figure 2A] and 4-fold change in fetal
microglia [figure 2B]). Decreased expression was
observed in M1-polarized cells, although results
were not statistically significant. Flow cytometry
experiments confirmed the increase in surface
protein expression of P2Y12 whereby the mean
fluorescence intensity was increased in M2-polarized
adult microglia (figure 2D) and M2-polarized fetal
microglia (figure 2E) compared to resting state.
ADP-induced intracellular calcium responses clearly
distinguish human microglia from macrophages and are
enhanced under alternatively polarizing M2 conditions.
To further validate the presence of functional P2Y12
receptors at the surface of human microglia, prominent
intracellular calcium ([Ca21]i) transients were observed
in human fetal microglia following a short application of
ADP (figure 3, A and B). Since ADP is also an agonist of
P2Y1 and P2Y13, the P2Y12-selective antagonist
PSB0739 was used to assess the selective contribution
of P2Y12 to ADP-evoked [Ca21]i responses. Treatment
with PSB0739 (10 mM) suppressed ADP-induced
[Ca21]i transients (figure 3, A and B), confirming
P2Y12 as the primary ADP receptor on human
microglia. In contrast, ADP-induced [Ca21]i responses
were small or absent in human MDMs, yet they
responded to ATP, likely through Gq-coupled P2Y2
receptors (figure 3, C and D). To measure across
species, similar experiments were performed using rat
microglia and produced similar transients (figure
e-1, B and C). Differential ADP-evoked [Ca21]i
responses were also observed between unpolarized,
M1-polarized, and M2-polarized human microglia.
Compared to unpolarized microglia, transients were
significantly larger in the M2-polarized cells (figure 3,
E–G). No differences between unpolarized and
M1-polarized microglia were observed (figure e-2).
In both unpolarized and M2-polarized cells,
ADP-induced [Ca21]i responses were blocked by a
selective P2Y12 antagonist.
ADP-induced migration of human microglia is
attenuated by a P2Y12 antagonist. To compare and
measure how migration of human myeloid cells
may be influenced by targeting P2Y12, microfluidic
chambers and Boyden-type assays were used. In
both assays, ADP induced a dose-dependent
increase in migration. Microglia pretreated with
PSB0739, a selective P2Y12 antagonist, significantly
decreased migration (figure 4, A–C); this was
further quantified using microfluidic chambers
(mean distance of 317 mm compared to 532 mm in
control; figure 4, D–F; figure e-3). No migratory
Figure 2 P2Y12 expression is upregulated in M2-polarized human microglia
(A, B) Using TaqMan quantitative real-time PCR, P2Y12 expression wasmeasured inM1- andM2-polarized humanmicroglia
(both adult and fetal). Compared to unpolarized (Unpol.) and M1-polarized cells, M2 microglia had significantly elevated
P2Y12 expression. Error bars represent mean 6 SEM; n 5 5/condition for microglia, n 5 3/condition for macrophages;
*p, 0.05, ***p, 0.001 compared to unpolarized. (C) Using flow cytometry, gating on the live human microglia population,
mean fluorescence intensity of P2Y12 was increased in M2-polarized (red line) adult microglia (D) and fetal microglia (E)
compared to resting conditions (blue line). Shaded histogram represents isotype control.
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responses were observed in peripheral-derived human
monocytes (figure e-4).
ADP-induced inflammatory responses in human
microglia are attenuated by a P2Y12 antagonist. To
determine whether pharmacologic inhibition of the
P2Y12 receptor could also influence inflammatory
responses, human microglia were exposed to ADP
in the presence or absence of PSB0739. In adult
and fetal microglia, ADP induced a dose-dependent
increase in TNF-a, with peak responses at 200
mM; no effect was observed with ATP (data not
shown). Preexposure of PSB0739 for 1 hour
resulted in a dose-dependent decrease in TNF-a
following stimulation with ADP (figure 5, A and
B). No effect was observed in MDMs (figure e-5).
A 75% decrease in TNF-a levels was measured in
adult and fetal microglia treated with 10 mM and
50 mM PSB0739, respectively. Decreased IL-6
expression was also measured; however, results were
not statistically significant (figure 5, C and D).
P2Y12 is highly expressed in CD681 cells during
parasitic brain infection. Previous reports have dem-
onstrated that parasitic helminth infections induce
a robust Th2 response.19–21 Considering Th2
cytokines are known to promote an M2-like cell
phenotype, we hypothesized that increased P2Y12
expression could be observed in a Th2-driven CNS
inflammatory condition such as Schistosoma
mekongi.22 Neuropathologic assessment demonstrated
the presence of chronic granulomata within the brain
parenchyma consisting of multinucleated giant cells
surrounding spaces containing chitinous helminthic
tissue and ova. Surrounding infiltrates consisted of
macrophages, lymphocytes, and plasma cells (figure 6A).
A marked reactive astrocytic response was seen in
the adjacent parenchyma. Within the granulomas,
immunohistochemistry experiments showed the
presence of several CD681/CD1631 (M2
marker) cells staining positive for P2Y12 (figure
6, B and C).
DISCUSSION In the inflamed CNS, activated resi-
dent microglia and blood-derived macrophages are
a heterogeneous population of cells that can
differentially contribute to pathophysiologic
mechanisms related to injury and repair. Despite
direct in vitro evidence supporting these observations,
the ability to reliably distinguish these cell types in
situ remains challenging. Several recent publications
have used novel genomic and proteomic technologies
to assign unique molecular signatures to different
myeloid cell populations.10,23 In a recent study,
detailed flow cytometry and immunohistochemical
analyses were performed using both naïve and
experimental autoimmune encephalomyelitis mice
chimeras (CX3CR1-GFP1/2-wildtype), whereby
peripheral monocytes were distinguishable from
microglia.24 In vivo, these experiments demonstrated
that resident GFP-microglia expressed P2Y12,
whereas recruited GFP1 monocytes did not.10 In the
Figure 3 ADP-evoked intracellular calcium responses discriminate between
human microglia and macrophages while increased ADP-evoked
intracellular calcium responses are observed in M2-polarized human
microglia
(A) Averaged traces of intracellular calcium ([Ca21]i) levels following a short application of
ADP in fetal human microglia. The P2Y12 selective antagonist PSB0739 strongly blocks
ADP-induced [Ca21]i. (B) Quantification of ADP-evoked [Ca21]i responses in the absence or
presence of PSB0739. (C) ADP-evoked [Ca21]i is minimal in human macrophages; however,
the cells respond strongly to ATP. (D) Quantification of ADP- and ATP-induced [Ca21]i tran-
sients. (E) Averaged traces of [Ca21]i levels following application of ADP in unpolarized
human fetal microglia and (F) comparison with responses to ADP in M2-polarized cells. (G)
ADP-evoked [Ca21]i responses in both unpolarized (Unpol.) and M2-polarized cells are
blocked by the P2Y12 antagonist PSB0739, summary quantification. Error bars represent
mean 6 SEM; n 5 14–35 cells/condition; ***p , 0.001.
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present study, we have validated P2Y12 as a receptor
that is exclusively expressed on human microglia. Using
human fetal and adult microglia, we report that P2Y12
expression is enhanced under alternatively activated
(M2; IL-4 & IL-13) conditions, mediates cell
migration, and participates in eliciting acute
proinflammatory response toward danger-associated
molecules that are released during CNS injury.
P2Y12 is a Gi/o-coupled purinergic receptor that
was initially identified on platelets and is responsible
for platelet activation during the blood clotting pro-
cess.25 P2Y12 antagonists have therefore been devel-
oped as antithrombotic agents to reduce the risk of
heart attack and stroke in high-risk patients. Beyond
platelets, P2Y12 expression was first described in
rodent microglia26 and has been implicated in cell
activation and migration.12,27,28 In normal rodent
microglia, LPS rapidly decreases P2Y12 expression,
suggesting that this receptor is a primary site by which
nucleotides induce very early migration in response to
pathogens and/or local injury.12 In P2Y122/2 mice,
microglia fail to migrate or extend processes toward
nucleotides in vitro and in vivo.12 P2Y12 knockdown
using morpholinos in zebrafish also resulted in a com-
plete block of microglial responses to injury.13
In our experiments, we confirmed that P2Y12 is
highly expressed on human microglia compared to
MDMs (figure 1). A direct comparison of P2Y12
expression between fetal and adult microglia revealed
that expression was greater in fetal cells than adult
microglia, which is consistent with results demon-
strating that P2Y12 expression declines with age.29
In response to ADP, P2Y12 receptor signaling indu-
ces a rapid release of [Ca1]i, which activates several
downstream signaling pathways.30 Using a selective
P2Y12 antagonist, PSB0739, we demonstrated that
ADP-induced [Ca1]i is dramatically abrogated in
human microglia. In MDMs, ADP did not induce
an increase in [Ca1]i, thus validating our initial
observations that P2Y12 expression was minimal to
negligible in blood-derived myeloid cells (figure 3). In
assays designed to measure P2Y12-dependent migra-
tion of human myeloid cells to ADP, an important
signal that promotes microglial migration and recruit-
ment, we observed that human microglia dose-
dependently migrate toward ADP. This response
was blocked with preexposure to the P2Y12 antago-
nist (figure 5).
Both microglia and macrophages are dependent
on distinct activation signals that are required to
induce different functional properties, often referred
to as M1 and M2 polarization. While rodent and
human macrophages can exhibit a spectrum of activa-
tion phenotypes both in vivo and in vitro,31 it should
be noted that tissue-resident myeloid cells (e.g.,
microglia) are a distinct myeloid cell subset that
Figure 4 ADP-induced migration of human microglia is blocked by a P2Y12 antagonist
(A) Using 10 mm cell migration chambers followed by crystal violet staining, ADP induced a significant migration of human microglia, whereas a 30-minute
preexposure of a P2Y12 antagonist (PSB0739; 10 mM) significantly decreased ADP-induced migration after 6 hours. Results were quantified in both adult
(B) and fetal (C) microglia. (D–F) Using silicon migration chambers, preexposure of a P2Y12 antagonist also significantly reduced migratory distance of
human microglia. For panels B and C, error bars represent mean 6 SEM; n 5 4/condition for microglia. For panel F, shaded box represents 95% confidence
interval; error bars represent minimum and maximum values. *p , 0.05, **p , 0.01, ***p , 0.001, ****p , 0.0001.
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requires further investigation with respect to how dif-
ferent modes of activation can influence their cellular
properties. For this reason, we have investigated how
IL-4 and IL-13 can lead to a microglia phenotype,
which is similar in an in situ microenvironment
known to express high levels of these cytokines. Pre-
viously, we have extensively profiled different activa-
tion states of human microglia and characterized
several different phenotypic markers (e.g., gene, mi-
croRNA, and protein) and functional properties.1,5 In
vitro, M1 microglia (IFN-g & LPS stimulated) are
implicated as potential mediators of tissue injury,
whereas M2 (IL-4/13) cells can produce anti-
inflammatory molecules and have been reported to
significantly mediate repair mechanisms in animal
models of stroke,32 spinal cord injury,18 and demye-
lination.17 Under proinflammatory conditions,
in vitro and in situ studies have demonstrated that
P2Y12 expression is decreased in rodent microglia
and results in the inability to migrate toward an
ADP gradient.28 In postmortem samples from the cere-
bral cortex of patients with multiple sclerosis (MS),
P2Y12 expression is absent in microglia/macrophages
within the lesion,33 but it is expressed in cells surround-
ing brain lesions. This decrease in P2Y12 expression
correlated with the extent of demyelination. In our
study, we confirmed that in the active MS lesion,
P2Y12 was not expressed (not shown), but it was
observed in CD681 cells in areas adjacent to the lesion
(figure e-6A). P2Y12 was not expressed in other glial
cells such as astrocytes (figure e-6B).
Our in vitro and in situ observations prompted
additional studies to examine how a Th2/M2 envi-
ronment might affect P2Y12 expression in situ. In
vivo studies have convincingly shown that parasitic
infection can promote both Th2 and M2-polarized
Figure 5 ADP-induced inflammatory responses require P2Y12 receptors in human microglia
Increasing concentrations of ADP (5, 50, and 200 mM) increased tumor necrosis factor (TNF) and interleukin (IL)-6 release in human adult microglia (A, C) and
fetal microglia (B, D), with maximal response reached at 200 mM after 6 hours. A 1-hour pretreatment with a P2Y12 receptor antagonist (PSB0739) dose-
dependently decreased TNF and IL-6 cytokine expression induced by ADP (200 mM) as measured by ELISAs. Error bars represent mean 6 SEM; n 5
4/condition; **p , 0.01 compared to ADP (200 mM) treatment alone.
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phenotypes34–36 and can attract the migration of M2
macrophages to parasite eggs and chitin.37 Using a
rare case of human S mekongi infection of the brain,22
we confirmed that P2Y121/CD1631 M2 cells were
present in regions circumscribing helminthic ova (fig-
ure 6). It is interesting that previous associations have
been made between parasite infection and disease-
relevant immune responses in MS. In MS, patients
infected by helminths have been shown to harbor
decreased proinflammatory T-cell responses38 and
increased inflammation-resolving regulatory B cells
producing IL-10, brain-derived neurotrophic factor,
and nerve growth factor.39 In addition, compared to
uninfected patients, clinical outcome measures are
improved in helminth-infected patients with MS.40–42
In this report, we have confirmed that P2Y12 is
selectively expressed on human microglia and can
be used as a marker to distinguish CNS-resident
microglia from blood-derived myeloid cells. P2Y12
expression on microglia is dependent on different
modes of activation such that an inflammatory envi-
ronment decreases expression whereas a Th2/M2
microenvironment increases expression. In response
to their endogenous ligand, ADP, human microglia
rapidly increase [Ca1]i, release proinflammatory
cytokines, and display significant migratory ability.
Application of a selective P2Y12 receptor antagonist
was demonstrated to reverse these functions. Our
findings provide insight into how the functional
properties of microglia differ from peripheral-
derived macrophages in the inflamed CNS. These
properties are in part controlled by their relative level
of P2Y12 expression, which may provide a novel tar-
geting strategy for treating CNS inflammatory
conditions.
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